◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PHAR

Pharming Group NV (PHAR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Pharming Group NV (PHAR) operates in the BIOTECHNOLOGY industry and is headquartered in Leiden, Netherlands with about 407 employees. Its market capitalization is roughly $811 million. In the fiscal year ended 2025-12-31, PHAR reported $376M in revenue and $3M in net income.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

Interactive charts & full statements → Open the PHAR valuation workbench →

PHAR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$365M	$376M	$297M	$245M	$206M	$199M	$212M	$189M	$155M	$108M	$17M	$12M	$26M	$9M	$14M	$4M	$1M	$0M	$1M	$1M	$0M
Gross Profit	$317M	$331M	$262M	$220M	$188M	$178M	$189M	$165M	$129M	$93M	$12M	$7M	$22M	$8M	$8M	($1M)	$1M	($4M)	($1M)	($36M)	($6M)
Gross Margin %	86.9%	87.9%	88.1%	89.7%	91.5%	89.4%	88.9%	87.4%	83.6%	86.1%	70.5%	55.7%	83.8%	83.8%	59.8%	-17.7%	83.9%	-837.0%	-83.2%	-3568.3%	-2931.6%
Operating Income (EBIT)	$13M	$21M	($4M)	($22M)	$10M	$19M	$76M	$68M	$43M	$26M	($12M)	($14M)	$3M	($10M)	($23M)	($24M)	($28M)	($40M)	($41M)	($36M)	($24M)
Operating Margin %	3.6%	5.5%	-1.2%	-9.1%	4.8%	9.6%	35.9%	36.0%	28.1%	24.4%	-72.7%	-118.5%	13.6%	-101.0%	-164.5%	-616.9%	-3692.2%	-8312.8%	-4437.8%	-3568.3%	-12267.4%
Net Income	$10M	$3M	($12M)	($11M)	$14M	$16M	$38M	$41M	$29M	($91M)	($18M)	($11M)	($7M)	($21M)	($32M)	($22M)	($67M)	($46M)	($36M)	($32M)	($24M)
Net Margin %	2.7%	0.8%	-4.0%	-4.3%	6.7%	8.0%	17.8%	21.4%	18.5%	-85.1%	-110.5%	-92.0%	-27.2%	-220.0%	-227.0%	-570.3%	-8763.5%	-9570.1%	-3946.5%	-3136.4%	-12582.4%
EBITDA	$42M	$35M	$16M	$10M	$34M	$49M	$58M	$71M	$25M	($76M)	($14M)	($9M)	($7M)	($16M)	($28M)	($23M)	($49M)	($34M)	($23M)	($28M)	($21M)
Earnings Per Share (EPS)	$0.13	$0.04	$-0.17	$-0.16	$0.16	$0.18	$0.47	$0.48	$0.35	$-1.46	$-0.36	$-0.21	$-0.14	$-0.45	$-3.47	$-3.74	$-19.91	$-31.39	$-31.60	$-27.56	$-22.50
Shares Outstanding (M)	70M	71M	69M	66M	84M	88M	81M	84M	82M	63M	52M	51M	50M	46M	9M	6M	3M	1M	1M	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHAR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$90M	$72M	$106M	$97M	$93M	$79M	$92.7B	$75M
Gross Profit	$76M	$66M	$85M	$90M	$84M	$71M	$80.5B	$68M
Gross Margin %	83.9%	90.8%	80.2%	92.7%	90.4%	89.5%	86.8%	90.9%
Operating Income (EBIT)	$0M	($5M)	$2M	$16M	$9M	($7M)	$6.6B	$3M
Operating Margin %	-0.1%	-7.3%	1.9%	16.2%	9.7%	-9.4%	7.1%	4.5%
Net Income	$2M	($5M)	$5M	$8M	$5M	($15M)	$2.9B	($1M)
Net Margin %	1.8%	-7.2%	5.0%	7.8%	5.0%	-18.6%	3.1%	-1.4%
EBITDA	$9M	$1M	$9M	$23M	$10M	($4M)	—	$7M
Earnings Per Share (EPS)	$0.02	$-0.07	$0.07	$0.11	$0.07	$-0.22	$44.62	$-0.02
Shares Outstanding (M)	70M	70M	76M	67M	67M	67M	—	65M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHAR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$32M	$55M	($2M)	($17M)	$22M	$38M	$84M	$74M	$46M	$46M	($11M)	($18M)	($3M)	($11M)	($14M)	($22M)	($3M)	($24M)	($14M)	($32M)	($25M)
Capital Expenditures (CapEx)	$0M	$1M	$1M	$1M	$2M	$17M	$15M	$25M	$4M	$7M	$2M	$1M	$0M	$0M	$1M	$1M	$1M	$0M	$1M	$1M	$4M
Free Cash Flow (FCF)	$31M	$54M	($3M)	($19M)	$20M	$21M	$68M	$49M	$42M	$39M	($12M)	($19M)	($3M)	($11M)	($14M)	($23M)	($4M)	($24M)	($15M)	($33M)	($30M)
FCF Margin %	8.5%	14.3%	-0.9%	-7.6%	10.0%	10.6%	32.2%	25.7%	27.2%	35.9%	-72.6%	-160.0%	-12.9%	-121.5%	-102.6%	-599.8%	-572.0%	-4995.3%	-1660.3%	-3247.0%	-15245.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHAR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($13M)	$2M	$11M	$32M	$12M	$0M	$9M	$10M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($13M)	$2M	$10M	$32M	$12M	$0M	$9M	$9M
FCF Margin %	-14.1%	2.4%	9.8%	32.9%	12.5%	-0.1%	0.0%	12.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHAR Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$468M	$500M	$414M	$463M	$426M	$450M	$343M	$256M	$214M	$199M	$133M	$63M	$68M	$43M	$22M	$32M	$50M	$80M	$93M	$167M	$104M
Cash & Cash Equivalents	$158M	$146M	$57M	$62M	$207M	$218M	$168M	$74M	$80M	$70M	$34M	$35M	$42M	$23M	$7M	$5M	$14M	$23M	$27M	$74M	$34M
Total Liabilities	$197M	$223M	$185M	$244M	$221M	$232M	$192M	$139M	$153M	$177M	$104M	$34M	$31M	$36M	$32M	$34M	$36M	$61M	$76M	$84M	$39M
Total Debt (Short + Long-Term)	$101M	$101M	$86M	$142M	$137M	$128M	$125M	$53M	$78M	$81M	$26M	$3M	$1M	$2M	$2M	$3M	$0M	$39M	$0M	$23M	$2M
Total Shareholders' Equity	$270M	$277M	$229M	$219M	$205M	$219M	$150M	$117M	$62M	$16M	$27M	$24M	$30M	$5M	($10M)	($2M)	$14M	$19M	$17M	$51M	$66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHAR viewer.

Other Companies in BIOTECHNOLOGY

OLMA · Olema Pharmaceuticals Inc — $859 million
WVE · Wave Life Sciences Ltd — $857 million
CADL · Candel Therapeutics Inc — $830 million
ACRS · Aclaris Therapeutics Inc — $818 million
CTMX · CytomX Therapeutics Inc — $808 million
CLYM · Climb Bio Inc — $807 million
FDMT · 4D Molecular Therapeutics Inc — $779 million
DBVT · DBV Technologies — $776 million

← PH0T All “P” companies PHARM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.